Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Two Regimens of Artemether-lumefantrine for the Treatment of Malaria in Pregnancy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria for non pregnant women:~* Age ≥18 and ≤ 45 years~* P. falciparum parasitemia ≥ 100 parasites/μL and less than 200.000 parasites/μL~* Hematocrit ≥21%~* Negative HIV test~* Negative pregnancy test\*~* Written informed consent provided~* Willing to stay for 3 or 5 days at the hospital and to comply with the follow-up schedule~Inclusion criteria for pregnant women (in addition to the above criteria except\*):~* Gestational Age ≥ 14 weeks confirmed by ultrasound~* Singleton viable fetus~Exclusion criteria for non-pregnant women:~* Severe malaria or signs of severe malaria~* Medical conditions requiring concomitant drug treatment or transfer to a different hospital~* Intake of artemether-lumefantrine within the two previous 2 weeks~* Known allergy to the study drugs~* Previous participation in this study or current participation in other studies~Exclusion criteria for pregnant women (in addition to the above criteria):~* Signs of labour~* Fetal abnormalities identified by ultrasound

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- 3-day artemether-lumefantrine (Type: ACTIVE_COMPARATOR): Standard artemether-lumefantrine regimen (3-day treatment)
- 5-day artemether-lumefantrine (Type: EXPERIMENTAL): Artemether-lumefantrine extended regimen (5-day treatment)

Based on this trial design, predict the completion outcome and termination type (if applicable).